Atria Wealth Solutions Inc. Buys 829 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Atria Wealth Solutions Inc. grew its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 14.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,423 shares of the company’s stock after acquiring an additional 829 shares during the period. Atria Wealth Solutions Inc.’s holdings in CRISPR Therapeutics were worth $402,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. increased its stake in shares of CRISPR Therapeutics by 21.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 33,378 shares of the company’s stock valued at $1,515,000 after buying an additional 5,948 shares during the period. Stratos Wealth Partners LTD. grew its position in shares of CRISPR Therapeutics by 28.2% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 5,580 shares of the company’s stock valued at $253,000 after buying an additional 1,226 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of CRISPR Therapeutics by 11.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,527 shares of the company’s stock valued at $841,000 after buying an additional 1,879 shares during the period. BluePath Capital Management LLC bought a new position in shares of CRISPR Therapeutics during the third quarter worth about $37,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of CRISPR Therapeutics by 10.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 184,854 shares of the company’s stock worth $8,391,000 after acquiring an additional 17,258 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on CRSP shares. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Royal Bank of Canada boosted their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Chardan Capital increased their price target on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Morgan Stanley upped their target price on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Finally, Mizuho lifted their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Stock Up 2.1 %

CRSP stock opened at $57.06 on Tuesday. The stock’s 50 day moving average is $67.17 and its 200-day moving average is $64.60. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm has a market capitalization of $4.84 billion, a PE ratio of -29.11 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. CRISPR Therapeutics’s revenue was up 3253.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.41) earnings per share. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Raju Prasad sold 3,524 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the sale, the chief financial officer now directly owns 6,476 shares of the company’s stock, valued at approximately $470,740.44. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 83,992 shares of company stock worth $6,132,335. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.